Acute Pain – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：148頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Acute Pain – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Acute Pain - Pipeline Review, H2 2012', provides an overview of the Acute Pain therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. 'Acute Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Acute Pain.
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Acute Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Acute Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Acute Pain - Pipeline Review, H2 2012', provides an overview of the Acute Pain therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. 'Acute Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Acute Pain.
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Acute Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Acute Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acute Pain Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Acute Pain 9
Acute Pain Therapeutics under Development by Companies 11
Acute Pain Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Acute Pain Therapeutics – Products under Development by Companies 20
Acute Pain Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Acute Pain Therapeutics Development 25
Abbott Laboratories 25
Nektar Therapeutics 26
Acusphere, Inc. 27
A.P. Pharma, Inc. 28
Pacira Pharmaceuticals, Inc. 29
AcelRx Pharmaceuticals, Inc. 30
Cubist Pharmaceuticals, Inc. 31
Sun Pharmaceutical Industries Limited 32
Anavex Life Sciences Corp. 33
NeurogesX, Inc. 34
Nuvo Research Inc. 35
CombinatoRx, Incorporated 36
Array BioPharma Inc. 37
Orexo AB 38
Intas Pharmaceuticals Ltd. 39
Advinus Therapeutics Pvt. Ltd. 40
Transdel Pharmaceuticals, Inc. 41
BIOALVO S.A. 42
AngioChem Inc. 43
Trevena, Inc. 44
QRxPharma Limited 45
Cara Therapeutics, Inc. 46
Xenome Ltd. 47
Iroko Pharmaceuticals, LLC 48
Xanodyne Pharmaceuticals, Inc. 49
Antibe Therapeutics, Inc. 50
Pierre Fabre Medicament 51
Troikaa Pharmaceuticals Ltd. 52
Nautilus Neurosciences, Inc. 53
RaQualia Pharma Inc. 54
Cytogel Pharma, LLC 55
Madeira Therapeutics 56
Acute Pain – Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
Ketotransdel - Drug Profile 62
CR 4056 - Drug Profile 64
BLV0704 - Drug Profile 65
Vicodin CR - Drug Profile 66
Nucynta - Drug Profile 68
ARRY-797 - Drug Profile 71
NGX-1576 - Drug Profile 73
NGX-9674 - Drug Profile 74
NGX-5752 - Drug Profile 75
NGX-6052 - Drug Profile 76
buprenorphine hydrochloride - Drug Profile 77
AI-525 - Drug Profile 78
PRO-571 - Drug Profile 79
ANAVEX-1007 - Drug Profile 80
IV CR845 - Drug Profile 81
XP21B - Drug Profile 83
MoxDuo IR - Drug Profile 84
Eptifibatide - Drug Profile 85
Xen2174 - Drug Profile 86
ANAVEX-1519 - Drug Profile 88
Ketamine - Drug Profile 89
ANG2002 - Drug Profile 90
K-Opioid Receptor Biased Ligand Program - Drug Profile 91
Sufentanil - Drug Profile 92
RQ-00000008 - Drug Profile 93
Topical Diclofenac Solution - Drug Profile 94
IN-PHARM-002 - Drug Profile 95
D-9998 - Drug Profile 96
NCE 1 - Drug Profile 97
NCE 2 - Drug Profile 98
IP 940 - Drug Profile 99
IP 880 - Drug Profile 100
Z-212 - Drug Profile 101
OX51 - Drug Profile 102
DepoNSAID - Drug Profile 103
Mu-Opiod Receptor Biased Ligand Program - Drug Profile 104
ARX-04 - Drug Profile 105
ANAVEX-1066 - Drug Profile 107
NRI-ANA - Drug Profile 108
MRX-7EAT - Drug Profile 109
THA903 - Drug Profile 111
Cyt-1010 - Drug Profile 112
NKTR-192 - Drug Profile 114
T109 - Drug Profile 115
ABT-594 - Drug Profile 116
RQ-00317076 - Drug Profile 118
ATB-346 - Drug Profile 119
Target 1 For Pain - Drug Profile 120
V0498TA01A - Drug Profile 121
CB-625 - Drug Profile 122
Acute Pain Therapeutics – Drug Profile Updates 123
Acute Pain Therapeutics – Discontinued Products 131
Acute Pain Therapeutics - Dormant Products 132
Acute Pain – Product Development Milestones 135
Featured News & Press Releases 135
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 144
Disclaimer 144
List of Tables
Number of Products Under Development for Acute Pain, H2 2012 13
Products under Development for Acute Pain – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Development by Companies, H2 2012 (Contd..1) 25
Products under Development by Companies, H2 2012 (Contd..2) 26
Products under Development by Companies, H2 2012 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Abbott Laboratories, H2 2012 29
Nektar Therapeutics, H2 2012 30
Acusphere, Inc., H2 2012 31
A.P. Pharma, Inc., H2 2012 32
Pacira Pharmaceuticals, Inc., H2 2012 33
AcelRx Pharmaceuticals, Inc., H2 2012 34
Cubist Pharmaceuticals, Inc., H2 2012 35
Sun Pharmaceutical Industries Limited, H2 2012 36
Anavex Life Sciences Corp., H2 2012 37
NeurogesX, Inc., H2 2012 38
Nuvo Research Inc., H2 2012 39
CombinatoRx, Incorporated, H2 2012 40
Array BioPharma Inc., H2 2012 41
Orexo AB, H2 2012 42
Intas Pharmaceuticals Ltd., H2 2012 43
Advinus Therapeutics Pvt. Ltd., H2 2012 44
Transdel Pharmaceuticals, Inc., H2 2012 45
BIOALVO S.A., H2 2012 46
AngioChem Inc., H2 2012 47
Trevena, Inc., H2 2012 48
QRxPharma Limited, H2 2012 49
Cara Therapeutics, Inc., H2 2012 50
Xenome Ltd., H2 2012 51
Iroko Pharmaceuticals, LLC, H2 2012 52
Xanodyne Pharmaceuticals, Inc., H2 2012 53
Antibe Therapeutics, Inc., H2 2012 54
Pierre Fabre Medicament, H2 2012 55
Troikaa Pharmaceuticals Ltd., H2 2012 56
Nautilus Neurosciences, Inc., H2 2012 57
RaQualia Pharma Inc., H2 2012 58
Cytogel Pharma, LLC, H2 2012 59
Madeira Therapeutics, H2 2012 60
Assessment by Monotherapy Products, H2 2012 61
Assessment by Stage and Route of Administration, H2 2012 63
Assessment by Stage and Molecule Type, H2 2012 65
Acute Pain Therapeutics – Drug Profile Updates 127
Acute Pain Therapeutics – Discontinued Products 135
Acute Pain Therapeutics – Dormant Products 136
Acute Pain Therapeutics – Dormant Products (Contd..1) 137
Acute Pain Therapeutics – Dormant Products (Contd..2) 138
List of Figures
Number of Products under Development for Acute Pain, H2 2012 13
Products under Development for Acute Pain – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Discovery and Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 61
Assessment by Route of Administration, H2 2012 62
Assessment by Stage and Route of Administration, H2 2012 63
Assessment by Molecule Type, H2 2012 64
Assessment by Stage and Molecule Type, H2 2012 65
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acute Pain Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Acute Pain 9
Acute Pain Therapeutics under Development by Companies 11
Acute Pain Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Acute Pain Therapeutics – Products under Development by Companies 20
Acute Pain Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Acute Pain Therapeutics Development 25
Abbott Laboratories 25
Nektar Therapeutics 26
Acusphere, Inc. 27
A.P. Pharma, Inc. 28
Pacira Pharmaceuticals, Inc. 29
AcelRx Pharmaceuticals, Inc. 30
Cubist Pharmaceuticals, Inc. 31
Sun Pharmaceutical Industries Limited 32
Anavex Life Sciences Corp. 33
NeurogesX, Inc. 34
Nuvo Research Inc. 35
CombinatoRx, Incorporated 36
Array BioPharma Inc. 37
Orexo AB 38
Intas Pharmaceuticals Ltd. 39
Advinus Therapeutics Pvt. Ltd. 40
Transdel Pharmaceuticals, Inc. 41
BIOALVO S.A. 42
AngioChem Inc. 43
Trevena, Inc. 44
QRxPharma Limited 45
Cara Therapeutics, Inc. 46
Xenome Ltd. 47
Iroko Pharmaceuticals, LLC 48
Xanodyne Pharmaceuticals, Inc. 49
Antibe Therapeutics, Inc. 50
Pierre Fabre Medicament 51
Troikaa Pharmaceuticals Ltd. 52
Nautilus Neurosciences, Inc. 53
RaQualia Pharma Inc. 54
Cytogel Pharma, LLC 55
Madeira Therapeutics 56
Acute Pain – Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
Ketotransdel - Drug Profile 62
CR 4056 - Drug Profile 64
BLV0704 - Drug Profile 65
Vicodin CR - Drug Profile 66
Nucynta - Drug Profile 68
ARRY-797 - Drug Profile 71
NGX-1576 - Drug Profile 73
NGX-9674 - Drug Profile 74
NGX-5752 - Drug Profile 75
NGX-6052 - Drug Profile 76
buprenorphine hydrochloride - Drug Profile 77
AI-525 - Drug Profile 78
PRO-571 - Drug Profile 79
ANAVEX-1007 - Drug Profile 80
IV CR845 - Drug Profile 81
XP21B - Drug Profile 83
MoxDuo IR - Drug Profile 84
Eptifibatide - Drug Profile 85
Xen2174 - Drug Profile 86
ANAVEX-1519 - Drug Profile 88
Ketamine - Drug Profile 89
ANG2002 - Drug Profile 90
K-Opioid Receptor Biased Ligand Program - Drug Profile 91
Sufentanil - Drug Profile 92
RQ-00000008 - Drug Profile 93
Topical Diclofenac Solution - Drug Profile 94
IN-PHARM-002 - Drug Profile 95
D-9998 - Drug Profile 96
NCE 1 - Drug Profile 97
NCE 2 - Drug Profile 98
IP 940 - Drug Profile 99
IP 880 - Drug Profile 100
Z-212 - Drug Profile 101
OX51 - Drug Profile 102
DepoNSAID - Drug Profile 103
Mu-Opiod Receptor Biased Ligand Program - Drug Profile 104
ARX-04 - Drug Profile 105
ANAVEX-1066 - Drug Profile 107
NRI-ANA - Drug Profile 108
MRX-7EAT - Drug Profile 109
THA903 - Drug Profile 111
Cyt-1010 - Drug Profile 112
NKTR-192 - Drug Profile 114
T109 - Drug Profile 115
ABT-594 - Drug Profile 116
RQ-00317076 - Drug Profile 118
ATB-346 - Drug Profile 119
Target 1 For Pain - Drug Profile 120
V0498TA01A - Drug Profile 121
CB-625 - Drug Profile 122
Acute Pain Therapeutics – Drug Profile Updates 123
Acute Pain Therapeutics – Discontinued Products 131
Acute Pain Therapeutics - Dormant Products 132
Acute Pain – Product Development Milestones 135
Featured News & Press Releases 135
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 144
Disclaimer 144
List of Tables
Number of Products Under Development for Acute Pain, H2 2012 13
Products under Development for Acute Pain – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Development by Companies, H2 2012 (Contd..1) 25
Products under Development by Companies, H2 2012 (Contd..2) 26
Products under Development by Companies, H2 2012 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Abbott Laboratories, H2 2012 29
Nektar Therapeutics, H2 2012 30
Acusphere, Inc., H2 2012 31
A.P. Pharma, Inc., H2 2012 32
Pacira Pharmaceuticals, Inc., H2 2012 33
AcelRx Pharmaceuticals, Inc., H2 2012 34
Cubist Pharmaceuticals, Inc., H2 2012 35
Sun Pharmaceutical Industries Limited, H2 2012 36
Anavex Life Sciences Corp., H2 2012 37
NeurogesX, Inc., H2 2012 38
Nuvo Research Inc., H2 2012 39
CombinatoRx, Incorporated, H2 2012 40
Array BioPharma Inc., H2 2012 41
Orexo AB, H2 2012 42
Intas Pharmaceuticals Ltd., H2 2012 43
Advinus Therapeutics Pvt. Ltd., H2 2012 44
Transdel Pharmaceuticals, Inc., H2 2012 45
BIOALVO S.A., H2 2012 46
AngioChem Inc., H2 2012 47
Trevena, Inc., H2 2012 48
QRxPharma Limited, H2 2012 49
Cara Therapeutics, Inc., H2 2012 50
Xenome Ltd., H2 2012 51
Iroko Pharmaceuticals, LLC, H2 2012 52
Xanodyne Pharmaceuticals, Inc., H2 2012 53
Antibe Therapeutics, Inc., H2 2012 54
Pierre Fabre Medicament, H2 2012 55
Troikaa Pharmaceuticals Ltd., H2 2012 56
Nautilus Neurosciences, Inc., H2 2012 57
RaQualia Pharma Inc., H2 2012 58
Cytogel Pharma, LLC, H2 2012 59
Madeira Therapeutics, H2 2012 60
Assessment by Monotherapy Products, H2 2012 61
Assessment by Stage and Route of Administration, H2 2012 63
Assessment by Stage and Molecule Type, H2 2012 65
Acute Pain Therapeutics – Drug Profile Updates 127
Acute Pain Therapeutics – Discontinued Products 135
Acute Pain Therapeutics – Dormant Products 136
Acute Pain Therapeutics – Dormant Products (Contd..1) 137
Acute Pain Therapeutics – Dormant Products (Contd..2) 138
List of Figures
Number of Products under Development for Acute Pain, H2 2012 13
Products under Development for Acute Pain – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Discovery and Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 61
Assessment by Route of Administration, H2 2012 62
Assessment by Stage and Route of Administration, H2 2012 63
Assessment by Molecule Type, H2 2012 64
Assessment by Stage and Molecule Type, H2 2012 65
